---
title: "Eli Lilly executives stated in a conference call that, at fixed exchange rates, revenue in the Europ"
description: "Eli Lilly executives stated in a conference call that, at fixed exchange rates, revenue in the European region grew by over 100%, reflecting strong market demand for the diabetes drug Mounjaro"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263546538.md"
published_at: "2025-10-30T14:13:30.000Z"
---

# Eli Lilly executives stated in a conference call that, at fixed exchange rates, revenue in the Europ

> Eli Lilly executives stated in a conference call that, at fixed exchange rates, revenue in the European region grew by over 100%, reflecting strong market demand for the diabetes drug Mounjaro

Eli Lilly executives stated in a conference call that, at fixed exchange rates, revenue in the European region grew by over 100%, reflecting strong market demand for the diabetes drug Mounjaro

### Related Stocks

- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 禮來公司 $LLY 的股票被 Assetmark Inc. 收購 | Assetmark Inc. 在第三季度將其在禮來的持股增加了 6.0%，目前持有 55,360 股，價值為 4224 萬美元。其他機構投資者也增持了股份，82.53% 的股票由對沖基金持有。禮來的股票開盤價為 1,040.12 美元，市值 | [Link](https://longbridge.com/en/news/275971336.md) |
| 禮來公司（LLY）建立了價值 15 億美元的減肥藥庫存 | 禮來（LLY）已準備好 15 億美元的庫存，以迎接其新減肥藥 Orforglipron 預計在四月獲得 FDA 批准。該公司計劃在今夏推出該藥，並進行大規模的營銷活動，以與諾和諾德的 Wegovy 競爭。分析師對禮來的股票給予了一致的強烈買 | [Link](https://longbridge.com/en/news/276070062.md) |
| 禮來公司宣佈 Taltz 和 Zepbound（Tirzepatide）取得了積極的頂線結果 | 禮來公司宣佈了 TOGETHER-PsO 3b 期臨牀試驗的積極頂線結果，顯示 Taltz（ixekizumab）和 Zepbound（tirzepatide）的組合顯著改善了中重度斑塊型銀屑病和肥胖成人的皮膚清除率和體重減輕。該治療在 3 | [Link](https://longbridge.com/en/news/276230105.md) |
| 禮來公司的一種實驗性抗癌藥物降低了早期肺癌患者的復發風險 | 禮來的第三階段 LIBRETTO-432 試驗顯示，Retevmo（selpercatinib）在早期非小細胞肺癌患者中顯著降低了復發風險。該試驗招募了 151 名患者，並顯示出改善的無事件生存期。過去一年，禮來股票上漲了 21.33%，交 | [Link](https://longbridge.com/en/news/276119494.md) |
| 禮來第四季度營收為 192.9 億美元，同比增長 43%。預計全年營收為 800 億至 830 億美元，市場預期為 777.1 億美元 | 禮來第四季度營收為 192.9 億美元，同比增長 43%。預計全年營收為 800 億至 830 億美元，市場預期為 777.1 億美元。 | [Link](https://longbridge.com/en/news/274805260.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.